21187-98-4 C15H21N3O3S Gliclazide CAS NO.21187-98-4

gliclazide basic information

hypoglycemic agents pharmacological effects pharmacokinetics synthetic method application adverse reactions contraindications precautions drug interactions

product name:	gliclazide
synonyms:	benzenesulfonamide, n-[[(hexahydrocyclopenta[c]pyrrol-2(1h)-yl)amino]carbonyl]-4-methyl-;gliclazide;glimicron;diamicron;1-(3-azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea;1-(3-azabicygclo[33.0]oct-3-yl)-3-o-tolylsulphonylurea;akos ncg1-0056;n-[[[hexahydrocylopenta[c]pyrrol-2(1h)-yl]amino]carbonyl]-4-methylbenzenesulfonamide
cas:	21187-98-4
mf:	c15h21n3o3s
mw:	323.41
einecs:	244-260-5
product categories:	pharmaceutical;active pharmaceutical ingredients;apis;intermediates & fine chemicals;pharmaceuticals;api's;potassium channel;aromatics;sulfur & selenium compounds;other apis;pharmaceutical intermediates
mol file:	21187-98-4.mol

gliclazide chemical properties

mp	163-169 °c(lit.)
storage temp.	-20°c freezer
solubility	methylene chloride: soluble
form	powder
color	white
cas database reference	21187-98-4(cas database reference)

safety information

hazard codes	xn,xi
risk statements	21-36/38-46-62-63
safety statements	25-26-36/37-53
wgk germany	2
rtecs	yt4500000

msds information

gliclazide usage and synthesis

hypoglycemic agents	gliclazide, chemical name is 1- (hexahydrocyclopenta [c] pyrrole -2 (1h) - yl) -3- (4-methylphenyl) sulfonyl urea, is the second generation of sulfur ureide oral hypoglycemic agents, and it also has dual function of hypoglycemic and improving blood clotting. it not only can improve the metabolism of diabetic patients, but also can improve or delay the occurrence of diabetic vascular complications. gliclazide was developed by the french servier company, and listed in france as early as 1972. its trade names are diamicron gliclazide, methanesulfonic bicyclic urea to g pancreas, methanesulfonic grid urea, glick that sa. it is mainly used for the treatment of the onset of diet and exercise alone control ineffective of adulthood, and no ketosis tendency of light, moderate the type ii diabetes. it also can improve diabetic retinopathy and metabolic disorders, vascular function. it can be used with biguanide oral hypoglycemic drugs, and used with insulin to treat insulin-dependent diabetes mellitus, in which condition that insulin dosage can be reduced. 1980s, it began to be supplied into the chinese market. now there has been more than 130 countries worldwide that registered and sold.
pharmacological effects	1. hypoglycemic effect: gliclazide is the second-generation oral sulfonylurea hypoglycemic agents. its role is more than ten times stronger than tolbutamide. mechanism of action is to stimulate pancreatic β cells to release insulin, and then the high blood sugar drops. this may be because that sulfonylurea combines with β cell surface receptor, and increases the activation and simultaneously improves the sensitivity of outer periphery of the target tissue to insulin. 2. it can reduce platelet aggregation and adhesion, and prevent fibrin depositing in the microvasculature. 3. it can lower cholesterol savings, and reduce plasma concentrations of arterial triphosphate glycerides and fatty acids. the role of the three not only can treat diabetes metabolic disorders, but also prevent and treat complications like the development and progression of diabetes-blood vessels, retinal, renal disease.
pharmacokinetics	the absorption of gliclazide is rapidly when it is taken orally. the plasma concentration peaks after two to six hours. plasma protein binding rate is 94.2%. τ1/2 is about 12 hours. gliclazide is mainly used in the liver metabolism, and its metabolites has no hypoglycemic effect. 98% is excreted by kidney in less than 48 hours, and the content of unchanged drug in the urine is less than 5%.
synthetic method	cyclopentane ortho anhydride as raw materials, ammoniates to obtain cyclopentane phthalimide. it reacts to obtain azabicyclo through catalytic reduction by catalysts like lialh4, kbh4/zncl2 or black platinum. and then azabicyclo reacts to give n-3-azabicyclo [3, 3, o] octane hydrochloride by nitrosation, zinc reduction. finally it reacts with toluene sulfonylurea to obtain gliclazide through condensation. figure 1 the synthetic route of gliclazide
application	1. for adults with type 2 diabetes, diabetes associated with obesity or vascular lesions. 2. hypoglycemic agents. it can be used for the treatment of non-insulin dependent diabetes mellitus. 3. hypoglycemic agents, non-insulin dependent diabetes mellitus. the above information is edited by the chemicalbook of ge qian.
adverse reactions	occasional mild nausea, vomiting, abdominal pain, constipation, diarrhea, erythema, urticaria, thrombocytopenia, neutropenia, anemia. most adverse reactions disappeared after withdrawal.
contraindications	1. forbidden for patients allergic to gliclazide or sulfonylureas, sulfa drugs. 2. forbidden for patients with type 1 diabetes. 3. forbidden for patients with diabetic pre-coma, diabetic ketoacidosis. 4. forbidden for patients with severe liver and kidney dysfunction. 5. forbidden for leukopenia patients. 6. forbidden for patients with stress situations like coma, severe burns, infection, trauma and major surgery. 7. forbidden for patients with pregnant and lactating women
precautions	1. when patients with type 2 diabetes have infection, trauma, surgery, stress situations and ketoacidosis and hyperosmolar nonketotic diabetic coma, insulin therapy should be used instead. 2. when the overdose of gliclazide, eating too little or strenuous exercise, you should take attention to prevent hypoglycemia. 3. you must regularly check blood sugar, urine, and take eye examinations. 4. when gliclazide is combined with anticoagulants, you should have regular blood clotting check.
drug interactions	when gliclazide is used with nonsteroidal anti-inflammatory drug (especially salicylates), sulfa antibiotic, double coumarin anticoagulants, monoamine oxidase inhibitors, β-blockers, tetracycline, chloramphenicol, dicyclohexyl b piperidine, clofibrate, ethanol and other drugs, its dosage should be reduced to avoid hypoglycemia reaction.
chemical properties	white cyrstalline solid
usage	antidiabetic, adhesion inhibitor
usage	a sulfonylurea hypoglycemic agent. used as an antidiabetic

gliclazide preparation products and raw materials

raw materials

diethyl oxalate-->sodium ethoxide-->diethyl malonate-->potassium borohydride-->p-toluenesulfonamide

hennan sunlake enterprise corporation is located in henan province , the central plain of china , which enjoys favorable geogeaphical position and convenient transportion, the com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .

sunlake is a professional manufacturer engaged in producing and selling chemicals,including organic & inorganic chemicals , pigments & dyestuffs , water treatment chemicals , food & feed additives and others . these products have been being well exported to europe , southeast asia , the middle east , africa , south america and some other countries and areas.

we sincerely welcome foreign friends to visit our plant for cooperation. with the idea of "quality first,credit priority, excellent service", we are highly acknowledged by customers for good quality and competitive price. more importantly , the company has a strong r & d team, who are professional engineers and scholars with ph. d. .so we are confident to serve you better with our high - quality products and professional team.

we are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market. we welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!